To estimate associations between longterm use of proton pump inhibitors (PPIs) and pneumonia incidence in older adults in primary care. DESIGN: Longitudinal analyses of electronic medical records. SETTING: England PARTICIPANTS: Individuals aged 60 and older in primary care receiving PPIs for 1 year or longer (N575,050) and age-and sex-matched controls (N575,050). MEASUREMENTS: Net hazard ratios for pneumonia incidence in Year 2 of treatment were estimated using the prior event rate ratio (PERR), which adjusts for pneumonia incidence differences before initiation of treatment. Inverse probability weighted models adjusted for 78 demographic, disease, medication, and healthcare usage measures. RESULTS: During the second year after initiating treatment, PPIs were associated with greater hazard of incident pneumonia (PERR-adjusted hazard ratio51.82, 95% confidence interval51.27-2.54), accounting for pretreatment pneumonia rates. Estimates were similar across age and comorbidity subgroups. Similar results were also obtained from propensity score-and inverse probability-weighted models. CONCLUSION: In a large cohort of older adults in primary care, PPI prescription was associated with greater risk of pneumonia in the second year of treatment. Results were robust across alternative analysis approaches. Controversies about the validity of reported short-term harms of PPIs should not divert attention from potential longterm effects of PPI prescriptions on older adults. J Am Geriatr Soc 66:1332-1338, 2018.
P roton pump inhibitors (PPIs) are widely prescribed to reduce gastric acid production and for gastroprotection, 1,2 but there is evidence of frequent prescribing of PPIs without adequate indication. 3 PPI use has been linked to higher rates of several conditions, including osteoporotic fractures, [4] [5] [6] cardiovascular disease, 7, 8 and Clostridium difficile infection. [7] [8] [9] PPIs act directly on H1/K1-ATPase enzymes, reducing acid secretion, but gastric acid plays a vital role in the innate response to bacterial infection. Without this protection, bacterial colonization occurs, 10 increasing the risk of bacterial micro-aspiration and pulmonary colonization. Several studies, including meta-analyses, have reported high risk of pneumonia soon after PPI therapy initiation, [11] [12] [13] [14] [15] although negative associations have also been reported. 16, 17 A recent observational study of the first year after PPI prescription 16 used the prior event rate ratio (PERR), [18] [19] [20] [21] which adjusts differences in postprescription pneumonia incidence between cases and controls with preexisting differences to correct for unmeasured confounding. That study used data from individuals in primary care in England and found that pneumonia rates increased during the first 30 days of PPI prescription (incidence rate ratio (IRR)51.19, 95% confidence interval (CI)51.14-1.25), but pneumonia rates were even higher during the 30 days immediately before the first PPI prescription (IRR51.92, 95% CI51.84-2.00), perhaps because the greater medical scrutiny of individuals with pneumonia led to more PPI prescribing for comorbidities, including medications commonly co-prescribed with PPIs. The PERR analysis, accounting for these prior differences, indicated no additional effect of PPIs on pneumonia risk in the 30 days or first year of treatment periods, but no data on longer-term effects have been reported.
Approximately 40% of elderly adults receive PPIs, and appropriate clinical indications may be lacking for up to 85% of PPIs prescribed. 22, 23 Pneumonia is a major cause of death, 24, 25 costing in excess of $17 billion per year in the United States alone. 26 It is therefore important to clarify associations between PPIs and pneumonia for short-and long-term exposure, especially in older adults, who may be most at risk from lack of barriers to respiratory infection. We therefore aimed to estimate long-term associations between PPI prescription and risk of pneumonia in individuals in primary care aged 60 and older, similarly applying the PERR approach to account for prior differences between PPI-treated individuals and controls.
METHODS

Data source
Data in this analysis were from Clinical Practice Research Datalink (CPRD) for England, a large de-identified database of primary care electronic medical records from participating practices. 27 Clinicians entered data as the main record of each consultation; the extract available for research includes basic demographic characteristics, diagnoses, prescriptions, vaccinations, and specialist referrals. The primary care data are linked for research purposes to each individual's hospital discharge diagnoses (from the National Health Service Hospital Episode Statistics) and death certificates from the Office of National Statistics database for individuals in England. Virtually all older adults in England are registered with a primary care practice and receive all routine prescriptions (all dispensed free of charge) through that practice.
CPRD received multiple research ethics committee approval (05/MRE04/87) for observational studies. National Information Governance Board's Ethics and Confidentiality Committee approval ECC 5-05 (a) 2012 also covers CPRD. Our study had gained prior approval from the CPRD Independent Scientific Advisory Committee (Protocol 15/210R).
STUDY POPULATION AND FOLLOW-UP
We selected individuals aged 60 and older who had PPI prescriptions recorded in each calendar quarter for 1 year or longer and had clinical records for 1 year or longer before first PPI prescription. Seventy-five thousand fifty individuals (Supplementary Figure 1S) in the database met these criteria (n531,202 men, n543,848 women). PPItreated individuals were 1-to-1 matched with 75,050 controls who had not received a PPI prescription. Matching was according to sex and year of birth only. The date of first PPI prescription was designated as the index date for analyses. After the matching, each treated individual's date of first PPI prescription was copied to his or her matched control.
Exposure and study end point PPIs (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole sodium) were identified in records based on the British National Formulary 28 Chapter 1.3.5, regardless of dosage.
Community-acquired pneumonia (pneumonia) has been defined previously elsewhere [29] [30] [31] based on ascertainment in linked primary care and hospital admission records. Pneumonia diagnosis 14 days or less after discharge was regarded as hospital-acquired pneumonia and excluded. 29, 30 Diagnoses of pneumonia 28 days or less from each other were considered the same event. A pneumonia diagnosis 30 days or less from an individual's registration with a practices was also excluded as possibly reflecting historical records. 30 
Details of statistical methods
An intention-to-treat approach including all individuals who received PPIs for at least 1 year, irrespective of details of treatment in the second year, was used for analyses to avoid biases that excluding those who stopped taking PPIs because of related adverse events might cause. As noted, 75,050 individuals with a PPI prescription for at least 1 year were included. In the second year, 64,364 of the 75,050 (85.8%) received prescriptions in at least 1 calendar quarter of the second year, with 55,961 (64.1%) receiving treatment during 3 of 4 calendar quarters of the second year.
PERR analyses were based on unadjusted Cox proportional hazard models, in accordance with validation studies. 19, 20, 36 Post-PPI hazard ratios (HRs) were adjusted by pre-PPI HRs using the PERR method ( Supplementary Figure 2S ) to account for unmeasured confounding and presented as PERR HRs and 95% confidence intervals (95% CIs) obtained using bootstrapping. 18, 19, 37 PERR analyses require independence of events in the pre-PPI period from risk of subsequent exposure. PERR also assumes that unmeasured confounding is time invariant.
20 PERR analyses analyzed post-PPI pneumonia risk adjusted by unmeasured confounding from the 24-to 13-month period before a PPI (Supplementary Figure 2S) . The number needed to harm was computed using an established formula 38 and bootstrapped to obtain 95% confidence limits. Subgroup analyses according to age and comorbidity were specified a priori in our original analysis application to CPRD.
Several alternative approaches were used in sensitivity analyses to test the robustness of our findings. Cox proportional hazard models adjusted by propensity scores 33, 34 (details in Supplementary Table 1) were performed in sensitivity analyses for the post-PPI period. Inverse-weighted probability models included 78 putative, measured confounders covering demographic characteristics, diagnoses, medication, and healthcare usage measures (details in Supplementary Table S1 ). The PERR-ALT method, 36 a variant of PERR analysis using a cross-over-like design with clustered (or paired) Cox models, with posttreatment events in treated individuals compared with pretreatment events in controls and vice versa, was also used. The PERR and propensity scoring approaches for addressing confounding in nonrandomized longitudinal studies have been reviewed elsewhere. 39 All statistical analyses were performed in Stata version 14 (Stata Corp., College Station, TX).
RESULTS
Records for 75,050 PPI-treated individuals and 75,050 matched controls were eligible for the primary analyses. Mean age in treated individuals and controls at index date was 7167.3, and 58% of PPI-treated and control participants were female (Table 1) . Treated participants had greater comorbidity (54.2% with Charlson Index 1) than controls (36.2%). Details of diagnosis and prescription differences between the treated and control groups can be found in Supplementary Table S1 .
Incidence rates
In the PPI-treated group, unadjusted pneumonia incidence rates were less than 6 per 1,000 person-years from 24 to 6 months before treatment but then rose considerably in the last 6 months before treatment (peak: 22 PPI-treated individuals per 1,000 person-years) (Figure 1 ). In the post-PPI treatment period, pneumonia incidence declined to a stable incidence of approximately 8 per 1,000 person-years in the first year but then showed a generally upward trend in the second year after PPI treatment. Pneumonia incidence in controls was lower (<4/1,000 person-years) and more stable throughout. Numbers of pneumonia events according to participant subgroup are shown in Supplementary  Table S2 . In Cox survival estimates for months 24 to 13 before a PPI prescription, pneumonia was more common in PPItreated individuals than controls (HR51.67, 95% CI51.37-2.02), but in the second year of the post-PPI period, this excess pneumonia risk was substantially larger (HR53.03, 95% CI52.6-3.53). The estimate of net long-term association according to the PERR calculation was significant (HR51.82, 95% CI51.27-2.54), suggesting substantial excess long-term pneumonia risk ( Table 2 ). The number needed to harm estimate for this result was 420 (95% CI5113-1,996).
The results in our prespecified age and comorbidity subgroups (Table 2) show broadly similar PERR estimates for the association between PPIs and pneumonia. Inspection of PERR CIs suggested no interactions and no main effect by these subgroups, although some subgroup-specific estimates had wide CIs, reflecting smaller numbers (Table 2) .
Sensitivity analysis
We used several alternative analysis approaches to check the robustness of our findings. Inverse probability weighting models and propensity scoring models were based on 78 measured potential confounders covering demographic characteristics, diagnoses, medication, and healthcare usage measures (details in Supplementary Table S1 ). The inverse probability-weighted models yielded results similar to those of PERR (Table 3) , as did propensity score modelling and adjustment for baseline variables. Primary analyses were reproduced using the PERR-ALT method (Supplementary  Table S5 ), which also produced similar results. Models of alternative time windows (months 7 to 24 before and after PPI treatment) also yielded similar results (Supplementary  Tables S3 and S4 ).
DISCUSSION
Main findings
Reported associations between PPI treatment and community-acquired pneumonia incidence during the first 30 days or 1 year of treatment may be due to biases, 16, 17 but little was known about longer-term risks. We have demonstrated for the first time a clear increase in longterm pneumonia incidence associated with ongoing PPI Figure 1 . Incidence rates of community acquired pneumonia according to months before and after index date in proton pump inhibitor-treated participants and controls (N5151,952). use after accounting for preexisting differences in pneumonia rates between treated and control groups. Reassuringly, the inverse probability-weighted and propensity score approaches accounting for 78 demographic, disease, medication, and healthcare usage measures in treated and control participants (in post-PPI Cox models) gave similar results, suggesting that the findings are robust. Although the number needed to harm was relatively large (420 participants for 12 months), given the high prevalence and frequent continuation of PPIs without good indication, 3 this number needed to harm represents a significant risk to older adults. Analyses according to age and comorbidity subgroups produced similar estimates, although larger samples are needed to confirm this.
Strengths and limitations
Our study has several strengths. First, the CPRD dataset used is representative of the general U.K. population, 27 so our results should have good external validity. As previously demonstrated, 19, 36 the PERR and PERR-ALT can approximate results of randomized controlled trials when suitably applied to observational clinical records. Our analyses were also designed to reduce confounding by focusing on long-term outcomes.
Inevitably there are limitations. Our matching of treatment groups (according to date of birth and sex only) may seem crude, but many potentially important differences between treatment and control groups go unrecorded in clinical records. The PERR method seeks to account for measured and unmeasured differences between groups by adjusting for differences in the outcome (pneumonia rates) before treatment started, so complex matching on baseline measures is redundant and was not used in validation of the PERR method. Our sensitivity analyses using propensity scoring and inverse probability-weighting approaches accounted for many measured potential confounders and provided similar results, but our list of potential measures did not include, for example, neurological diseases other than stroke that might increase risk of outpatient aspiration, and better measures of this and other risks should be used in future studies. Addition of a falsification analysis, using a condition not related to PPI exposure, could strengthen future work, although identifying a repeatedevent condition suitable for PERR analysis and potentially being exposed to similar biases to pneumonia would be challenging.
This study used prescription records from primary care and therefore omitted individuals who obtained overthe-counter PPIs, but PPIs are sold in small packs over the counter in England, and long-term use would be expensive. Because older adults receive free prescriptions and free consultations in the U.K. National Health Services, it is likely that our treatment group selection identified the great majority of long-term PPI use. We were also not able to control for adherence to treatment, but over-thecounter use and nonadherence would, in general, tend to reduce estimated effect sizes and are implausible explanations for the excess pneumonia risks identified. Data on indications and daily doses are complex and incomplete in the CPRD data, but accounting for these factors may strengthen future work. There may be drug-drug interactions modifying the effects of PPIs, which could be examined in future work. Furthermore, the PERR method cannot address time-dependent confounding. By excluding the year before PPI therapy in the main analysis, we reduced the risk of indication biases, but not longer-term time-dependent confounding, although the consistency of our results across the differing analysis approaches used suggests that such effects are likely to be small.
Comparison with previous literature
The safety of PPIs has been assessed using records from CPRD (e.g.), 16 retrospective data from randomized controlled trials, 40 and several meta-analytical and population-based studies, 12, 13, 41, 42 including a metaanalytical multiple-database study of individuals treated with nonsteroidal antiinflammatory drugs 1 and a study of individuals with nontraumatic intracranial hemorrhage. 2 Conclusions on PPI safety have been derived mainly from observational research and have led to conflicting suggestions on the role of confounding by indication in the association between PPIs and pneumonia. [15] [16] [17] Observational studies to date, including meta-analyses, have reported on approximately 30% greater PPI-related risk of pneumonia. [11] [12] [13] As noted, a study 16 of the first year of PPI treatment found higher rates of pneumonia before PPI initiation, which biased posttreatment HR estimates. A meta-analytical study 17 suggested similar confounding as 
CONCLUSIONS
Pneumonia risk is greater with long-term PPI therapy in older adults in primary care, independent of excess pneumonia rates immediately before first PPI receipt. In our cohort, the excess risk was statistically similar across age and comorbidity groups, but more work is needed to identify individuals at highest risk.
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